CAJ | 학술논문

肺癌是全世界的高发癌症,5年生存率仅为10%左右,主要原因是肺癌在发现时多为中晚期,失去了手术时机.化疗成为晚期肺癌治疗的主要手段,但是其有效率较低,其中癌细胞对化疗药物的多药耐药成为取得满意疗效的重要障碍.国内外诸多文献探讨关于肺癌耐药相关基因及蛋白的表达与非小细胞肺癌的关系,诸如P-糖蛋白、多药耐药相关蛋白、肺耐药蛋白等,目前已有比较明确的研究结粜.本文主要探讨拓扑异构酶Ⅱ、谷胱甘肽-S-转移酶π、环氧化酶2、β-微管蛋白、低氧诱导因子1α等在肺癌中的表达及其临床意义,从而为非小细胞肺癌化疗耐药研究与临床诊治提供参考.
폐암시전세계적고발암증,5년생존솔부위10%좌우,주요원인시폐암재발현시다위중만기,실거료수술시궤.화료성위만기폐암치료적주요수단,단시기유효솔교저,기중암세포대화료약물적다약내약성위취득만의료효적중요장애.국내외제다문헌탐토관우폐암내약상관기인급단백적표체여비소세포폐암적관계,제여P-당단백、다약내약상관단백、폐내약단백등,목전이유비교명학적연구결조.본문주요탐토탁복이구매Ⅱ、곡광감태-S-전이매π、배양화매2、β-미관단백、저양유도인자1α등재폐암중적표체급기림상의의,종이위비소세포폐암화료내약연구여림상진치제공삼고.
Lung cancer is one of the highest incidence cancers all over the world.Five-year survival rate of patients with lung cancer is only about 1 0%,because most patients with lung cancer are in the middle or late stage when they are diagnosed,and lose the operation opportunity.So,chemotherapy becomes the major countermeasure for lung cancer.But multidrug resistance of cancer cell is the major obstacle for chemotherapeutics,leading to lower efficiency.Previous studies have shown that the expressions of muhidrug resistance-associated genes and proteins are connected with non-small cell lung cancer,including P-glycoprotein.multidrug resistance-associated protein and lung resistance protein.This review focuses on the expression and clinical significance of topoisomeraseⅡ,glutathione-S-transferase π,eyclooxygenase-2,β-tubulin and hypoxia inducible factor-1α in lung cancer,and provides some information for the multidrug resistance of chemotherapy and clinical diagnosis and treatment of non-small cell lung cancer.